Evidence map›Paper›PMID 41518408›Full record

ArticleMikrochimica acta2026

Disposable electrochemical panel immunosensing systems for the simultaneous detection of potential biomarkers of ovarian cancer.

Melike Bilgi Kamaç, Ayşenur Yılmaz Kabaca, Merve Yılmaz Çılçar, Muhammed Altun, Mustafa Kemal Sezgintürk

Abstract read
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melike Bilgi KamaçFaculty of Science, Chemistry Department, Çankırı Karatekin University, Çankırı, 18100, Türkiye. melikesahin@karatekin.edu.tr.
Ayşenur Yılmaz KabacaŞabanözü Vocational School, Department of Medical Laboratory Techniques, Çankırı Karatekin University, Çankırı, 18000, Türkiye.
Merve Yılmaz ÇılçarFaculty of Science, Chemistry Department, Çankırı Karatekin University, Çankırı, 18100, Türkiye.
Muhammed AltunEldivan Vocational School of Health Services, Department of First and Emergency, Çankırı Karatekin University, Çankırı, 18000, Türkiye.
Mustafa Kemal SezgintürkFaculty of Engineering, Bioengineering Department, Çanakkale Onsekiz Mart University, Çanakkale, 17000, Türkiye. msezginturk@comu.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid, low-cost, practical, disposable electrochemical panel immunosensor systems were developed for the individual and simultaneous determination of anterior gradient-2 protein (AGR2), folate receptor alpha (FOLR1), glycodelin (GLY), and soluble mesothelin-associated protein (SMRP), which are significantly increased in physiological fluids, particularly in ovarian cancer, and are potential biomarkers in the diagnosis of specific cancer types. To reduce the cost of the panel immunosensor system, the electrodes were hand-fabricated (HSPE), and then the HSPE surfaces were modified with gold nanoparticles (AuNPs). Surface analyses (SEM, XPS, FTIR) have confirmed that the sensor was manufactured robustly. The electrochemical characterization and analysis of the immunosensors were performed using electrochemical impedance spectroscopy, cyclic voltammetry, and differential pulse voltammetry methods. Optimal operating conditions (antibody concentration, antigen, and antibody incubation times) were determined for the prepared single immunosensors. Detection limits, linear detection ranges, selectivity, shelf lives, repeatability, and reproducibility of single and panel immunosensors were determined. The clinical validity of the multi-platform was confirmed by recoveries of over 95% in human serum samples and by ELISA. In this study, low-cost electrochemical panel systems that enable the simultaneous determination of AGR2, GLY, FOLR1, and SMRP biomarkers with high selectivity and accuracy, a wide linear range (1-500 pg mL⁻¹), low detection limits, and good reproducibility were produced for the first time.

Indexed as

Biomarkers, TumorBiosensing TechniquesElectrochemical TechniquesOvarian NeoplasmsAntibodies, ImmobilizedElectrodesFemaleFolate Receptor 1GlycoproteinsGoldGPI-Linked ProteinsHumansImmunoassayLimit of DetectionMesothelinMetal NanoparticlesAGR2 protein, humanAntibodies, ImmobilizedBiomarkers, TumorFolate Receptor 1FOLR1 protein, humanGlycoproteinsGoldGPI-Linked ProteinsMesothelinMSLN protein, humanMucoproteinsOncogene ProteinsProteinsAGR2FOLR1GLYOvarian cancerPanel immunosensorSMRP

Identifiers

PMID41518408
PMCPMC12790523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.